Renaissance Technologies LLC Has $3.32 Million Stock Position in Insmed, Inc. $INSM

Renaissance Technologies LLC lowered its position in Insmed, Inc. (NASDAQ:INSM) by 21.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,300 shares of the biopharmaceutical company’s stock after selling 5,600 shares during the quarter. Renaissance Technologies LLC’s holdings in Insmed were worth $3,319,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. CIBC Private Wealth Group LLC increased its holdings in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the last quarter. Reflection Asset Management acquired a new stake in Insmed in the fourth quarter valued at approximately $30,000. Raiffeisen Bank International AG acquired a new stake in Insmed in the fourth quarter valued at approximately $32,000. Larson Financial Group LLC grew its position in Insmed by 137.0% in the fourth quarter. Larson Financial Group LLC now owns 256 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 148 shares in the last quarter. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA bought a new stake in Insmed in the fourth quarter worth approximately $49,000.

Insider Activity at Insmed

In related news, CEO William Lewis sold 21,398 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $103.32, for a total transaction of $2,210,841.36. Following the completion of the transaction, the chief executive officer directly owned 258,917 shares in the company, valued at $26,751,304.44. This represents a 7.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Sara Bonstein sold 2,404 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $245,857.08. Following the completion of the sale, the chief financial officer directly owned 69,082 shares of the company’s stock, valued at approximately $7,065,016.14. This trade represents a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 54,590 shares of company stock valued at $5,793,738 in the last 90 days. 2.10% of the stock is owned by company insiders.

Insmed Stock Performance

INSM opened at $131.10 on Friday. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The stock’s 50 day moving average price is $105.14 and its two-hundred day moving average price is $129.23. The firm has a market capitalization of $28.42 billion, a P/E ratio of -31.90 and a beta of 0.81. Insmed, Inc. has a 12-month low of $90.39 and a 12-month high of $212.75.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.61. Insmed had a negative return on equity of 122.43% and a negative net margin of 76.94%.The company had revenue of $425.49 million during the quarter, compared to analyst estimates of $395.50 million. During the same period in the previous year, the company earned ($1.70) earnings per share. The company’s quarterly revenue was up 296.1% compared to the same quarter last year. On average, equities analysts forecast that Insmed, Inc. will post -2.37 earnings per share for the current year.

Analyst Ratings Changes

INSM has been the topic of several analyst reports. Jefferies Financial Group restated a “buy” rating and set a $175.00 price target on shares of Insmed in a research note on Thursday. Morgan Stanley reiterated an “overweight” rating and issued a $218.00 price objective on shares of Insmed in a report on Friday. BMO Capital Markets started coverage on Insmed in a report on Monday, July 20th. They set an “outperform” rating and a $192.00 target price on the stock. Evercore reaffirmed an “outperform” rating and issued a $170.00 price target on shares of Insmed in a research report on Friday. Finally, JPMorgan Chase & Co. decreased their price target on Insmed from $180.00 to $179.00 and set an “overweight” rating for the company in a research note on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $205.26.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: BRINSUPRI sales significantly exceeded expectations. Second-quarter revenue reached $309.2 million, up 49% from the first quarter, reflecting strong commercial uptake of the company’s bronchiectasis treatment. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion-$1.40 billion and increased its peak-sales estimate to more than $7 billion. Insmed Second-Quarter 2026 Results
• Positive Sentiment: Insmed beat quarterly estimates. Total revenue was $425.5 million, up 296.1% year over year and above the approximately $393.7 million consensus forecast. The company reported a loss of $0.06 per share, substantially narrower than the expected $0.67 loss and the $1.70 loss recorded a year earlier. Insmed Tops Q2 Earnings Estimates
• Positive Sentiment: Long-term growth expectations improved. Insmed lifted its combined peak-revenue outlook for BRINSUPRI, TPIP and ARIKAYCE to more than $14 billion, including over $6 billion for TPIP. It maintained 2026 ARIKAYCE revenue guidance of $450 million-$470 million and provided total 2026 revenue guidance of approximately $1.7 billion-$1.9 billion.
• Positive Sentiment: Trading activity signaled strong investor interest. Call-option volume rose roughly 469% above average, while reports described the stock as gaining about 30%-34% following the earnings release. Analysts also maintained an overall “Buy” recommendation.
• Neutral Sentiment: Profitability remains limited. Despite the improved loss, Insmed continues to report negative net income and return on equity as it invests in developing and commercializing its pipeline.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.